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In an interesting randomized clinical trial (RCT), Donnino
et al. [1] studied a mixed out-of-hospital cardiac arrest
and in-hospital cardiac arrest (IHCA) population and
found no hydrocortisone versus placebo hemodynamic or
in-hospital outcome benefit. In the hydrocortisone group,
the median time to study intervention was 9.9 h after re-
turn of spontaneous circulation (ROSC) [1]. This time lag
probably exceeds the therapeutic window for the preven-
tion of detrimental episodes of early post-resuscitation
hypotension [2] through a mean arterial pressure (MAP)-
stabilizing effect of steroids [3, 4].
Analyses of pooled post-resuscitation shock data
from our IHCA vasopressin-steroids-epinephrine (VSE)
RCTs [3, 4] also showed no between-group differences in
the time to, or proportions of, discontinuation of vaso-
pressors, and post-ROSC day 1 hemodynamic support
(Table 1). However, VSE patients had higher, early post-
ROSC systolic arterial pressure (SAP) and MAP during
post-resuscitation follow-up [3, 4]. This reflected an
improved hemodynamic response to similar vasopres-
sor support titrated to a “wide” MAP range of 70–
100 mmHg [4].
Recordings of “early post-ROSC SAP >90 mmHg”
(i.e., “absence of early post-resuscitation hypotension”
[2]) and “≥1 recorded/analyzed, day 1 MAP value of
>80 mmHg [2]” were significantly more frequent in
VSE patients than controls. Importantly, such SAP/
MAP levels corresponded to more frequent survival to
hospital discharge with favorable neurological outcome
[4] (Table 1).
Early post-resuscitation hemodynamics of VSE patients
could be partly attributable to the steroids-vasopressin
combination during cardiopulmonary resuscitation (CPR)
[3, 4]. However, a previously postulated major CPR-VSE
effect, i.e., shorter advanced life support duration [4],
possibly leading to attenuated post-resuscitation car-
diovascular dysfunction was not clear in the current
subgroup analysis (Table 1). Hence, according to the
short (i.e., 24 min) half-life of vasopressin, we propose
that the more frequent day 1 MAP >80 mmHg was
largely due to a post-ROSC steroid-induced augmenta-
tion of vascular responsiveness to vasopressors [3, 4].
A mediation analysis of VSE outcome benefit through
day 1 MAP is warranted. Analysis of day 1 MAP data
from the study by Donnino et al. might causally link
between-RCT differences in corticosteroid timing with
differences in survival/neurological outcome results
[1, 3, 4].
Post-resuscitation disease is a “sepsis-like” syndrome.
In sepsis, acute kidney injury severity is associated with
mortality and elevated interleukin (IL)-6. Furthermore,
high post-ROSC IL-6 is associated with organ dysfunc-
tion and poor long-term outcomes [5]. Notably, post-
resuscitation hydrocortisone has been associated with
reduced IL-6 levels [1, 3], and VSE patients versus con-
trols had more renal failure-free days [3, 4].
Conclusively, available evidence prompts toward fur-
ther evaluation of early, stress-dose steroids in cardiac
arrest.
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Table 1 Pooled results (from [3] and [4]) on early post-enrollment hemodynamics in survivors for ≥4 h with post-resuscitation shock
Survivors for ≥4 h with post-resuscitation shocka VSE group (n = 103) Control group (n = 88) P value
Time to discontinuation of vasopressors (days), median (IQR)b 4 (2–8) 3 (2–6) 0.86
Discontinuation of vasopressors during follow-up, n (%) 43 (41.7) 34 (38.6) 0.77
Estimated cumulative vasopressor dose (μg/kg) over the first 24 h post-ROSC,
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ALS duration (min), median (IQR) 10 (6–16) 12 (6–20) 0.11
SAP >90 mmHg (n = 116) SAP ≤90 mmHg (n = 50) P value
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Survival to hospital discharge with CPC score of 1 or 2, n (%) 25 (21.4) 4 (5.9) 0.006
Data reported as n (%) were analyzed with the Fisher’s exact test; data reported as median (IQR) were analyzed with the Mann-Whitney exact U test; and data
reported as mean ± SD were analyzed with the independent samples t test
aDefined as sustained (>4 h), new post-arrest circulatory failure or post-arrest need for ≥50 % increase in any pre-arrest vasopressor/inotropic support targeted to
MAP >70 mmHg [3, 4]
bDefined as number of days from study enrollment until the first circulatory failure-free day; the latter corresponds to a sequential organ failure assessment (SOFA)
circulatory subscore <3; in both studies [3, 4], the SOFA score was determined daily through follow-up days 1–60 post-randomization
cWith respect to [3]: average daily infusion rates (IRs) of vasopressors were already available as they were calculated by the investigators who conducted the
follow-up; corresponding results were reported in the supplement of the originally published article. Consequently, Day 1 dose of a vasopressor (VD) (μg/kg) =
average daily IR (μg/kg/min) × 1440 (min)
dWith respect to [4]: for patients with IR data (μg/kg/min) available at 20 min post-ROSC (IR20M), 4 h post-ROSC (IR4H), and 24 h post-ROSC (IR24H) (n = 108), VD
(μg/kg) was estimated as follows: VD = average (IR20M; IR4H) × 240 (min) + average (IR4H; IR24H) × 1200 (min). For patients with available IR20M and IR4H (n = 39),
VD (μg/kg) was estimated as follows: VD = average (IR20M; IR4H) × 240 (min) + IR4H × (number of min until death after the completion of 4-h survival). For patients
with available IR20M only (n = 1), VD (μg/kg) was estimated as follows: VD = IR20M × (number of min until death)
eFor both [3] and [4], total day 1 VD (μg/kg) was calculated as follows [1]: VD = norepinephrine (μg/kg) + dopamine/2 (μg/kg) + epinephrine (μg/kg)
ALS advanced life support, CPC cerebral performance category, IQR interquartile range, MAP mean arterial pressure, ROSC return of spontaneous circulation, SAP
systolic arterial pressure, SD standard deviation, VSE vasopressin-steroids-epinephrine
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